Current status of organoid culture in urological malignancy

Tse, Ryan Tsz‐Hei; Zhao, Hongda; Wong, Christine Yim‐Ping; Chiu, Peter Ka‐Fung; Teoh, Jeremy Yuen‐Chun; Ng, Chi‐Fai

doi:10.1111/iju.14727

Cited by 4 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have been proposed as avatars to capture individual patient responses to therapy and for their accuracy to recapitulate cancer heterogeneity [ 14 ]. Moreover, they take into account the wider tumor microenvironment, that can modulate treatment response to chemotherapy or even immunotherapy [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma

Séraudie,

Pillet,

Cesana

et al. 2023

Cell Death Dis

View full text Add to dashboard Cite

Clear cell Renal Cell Carcinoma (ccRCC) is one of the most prevalent kidney cancers, which is often asymptomatic and thus discovered at a metastatic state (mRCC). mRCC are highly heterogeneous tumors composed of subclonal populations that lead to poor treatment response rate. Several recent works explored the potential of ccRCC tumoroids culture derived from patients. However, these models were produced following a scaffold-based method using collagen I or Matrigel that exhibit lot variability and whose complexity could induce treatment response modifications and phenotypic alterations. Following the observation that ccRCC tumoroids can create their own niche by secreting extracellular matrix components, we developed the first scaffold-free tumoroid model of ccRCC tumors. Tumoroids from mice as well as from human tumors were generated with high success rate (≥90%) using a magnetic suspension method and standard culture media. Immunofluorescence analysis revealed their self-organization capacities to maintain multiple tumor-resident cell types, including endothelial progenitor cells. Transcriptomic analysis showed the reproducibility of the method highlighting that the majority of gene expression patterns was conserved in tumoroids compared to their matching tumor tissue. Moreover, this model enables to evaluate drug effects and invasiveness of renal cancer cells in a 3D context, providing a robust preclinical tool for drug screening and biomarker assessment in line with alternative ex vivo methods like tumor tissue slice culture or in vivo xenograft models.

show abstract

Section: Discussionmentioning

confidence: 99%

A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma

Séraudie,

Pillet,

Cesana

et al. 2023

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…They have been proposed as avatars to capture individual patient responses to therapy and for their accuracy to recapitulate cancer heterogeneity [14]. Moreover, they take into account the wider tumor microenvironment, that can modulate treatment response to chemotherapy or even immunotherapy [55].…”

Section: Discussionmentioning

confidence: 99%

A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma

Filhol

Séraudie

Pillet

et al. 2023

Preprint

View full text Add to dashboard Cite

Clear cell Renal Cell Carcinoma (ccRCC) is one of the most prevalent kidney cancers, which is often asymptomatic and thus discovered at a metastatic state (mRCC). mRCC are highly heterogeneous tumors composed of subclonal populations that lead to poor treatment response rate. Several recent works explored the potential of ccRCC tumoroids culture derived from patients. However, these models were produced following a scaffold-based method using collagen I or Matrigel that exhibit lot variability and whose complexity could induce treatment response modifications and phenotypic alterations. Following the observation that ccRCC tumoroids can create their own niche by secreting extracellular matrix components, we developed the first scaffold-free tumoroid model of ccRCC tumors. Tumoroids from mice as well as from human tumors were generated with high success rate (≥90 %) using a magnetic suspension method and standard culture media. Immunofluorescence analysis revealed their self-organization capacities to maintain multiple tumor-resident cell types, including endothelial progenitor cells. Transcriptomic analysis showed the reproducibility of the method highlighting that the majority of gene expression patternswas conserved in tumoroids compared to their matching tumor tissue. Moreover, this model enables to evaluate drug effects and invasiveness of renal cancer cells in a 3D context, providing a robust preclinical tool for drug screening and biomarker assessment in line with alternative ex vivo methods like tumor tissue slice culture or in vivoxenograft models.

show abstract

“…Patient derived organoid models have been applied in cancer research in different urological cancers by different groups and the results had primed us to a new understanding of cancer biology and tumor genetics. 16 , 17 , 18 Nonetheless, limited studies focused on the establishment and application of RCC organoid models. The development of patient derived RCC organoid model was in fact just started to be elucidated since 2015.…”

Section: Introductionmentioning

confidence: 99%

The establishment of kidney cancer organoid line in drug testing

Tse,

Wong,

Ding

et al. 2024

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

IntroductionKidney cancer is a common urological malignancy worldwide with an increasing incidence in recent years. Among all subtypes, renal cell carcinoma (RCC) represents the most predominant malignancy in kidney. Clinicians faced a major challenge to select the most effective and suitable treatment regime for patients from a wide range of modalities, despite improved understanding and diagnosis of RCC.ObjectiveRecently, organoid culture gained more interest as the 3D model is shown to be highly patient specific which is hypothetically beneficial to the investigation of precision medicine. Nonetheless, the development and application of organotypic culture in RCC is still immature, therefore, the primary objective of this study was to establish an organoid model for RCC.Materials and MethodsPatients diagnosed with renal tumor and underwent surgical intervention were recruited. RCC specimen was collected and derived into organoids. Derived organoids were validated by histological examminations, sequencing and xenograft. Drug response of organoids were compared with resistance cell line and patients' clinical outcomes.ResultsOur results demonstrated that organoids could be successfully derived from renal tumor and they exhibited high concordance in terms of immunoexpressional patterns. Sequencing results also depicted concordant mutations of driver genes in both organoids and parental tumor tissues. Critical and novel growth factors were discovered during the establishment of organoid model. Besides, organoids derived from renal tumor exhibited tumorigenic properties in vivo. In addition, organoids recapitulated patient's in vivo drug resistance and served as a platform to predict responsiveness of other therapeutic agents.ConclusionOur RCC organoid model recaptiluated histological and genetic features observed in primary tumors. It also served as a potential platform in drug screening for RCC patients, though future studies are necessary before translating the outcomes into clinical practices.

show abstract

Current status of organoid culture in urological malignancy

Cited by 4 publications

References 81 publications

A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma

A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma

A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma

The establishment of kidney cancer organoid line in drug testing

Contact Info

Product

Resources

About